M1388 – Patients with documentation of an exam performed for recurrence of melanoma

Long description

Patients with documentation of an exam performed for recurrence of melanoma

Short description

Pt doc exm rec melmn

Pricing indicator

00 Not separately priced by Part B (bundled, not covered or Part A only)

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

Z2 Undefined codes

Added

January 1, 2025

Last change

January 1, 2025 – No change

Nearby M codes

• M1380 – Filled at least two prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "denominator note" or the long-acting injectable antipsychotic medications listed under "denominator note"
• M1381 – Patients with secondary stroke (e.g., a subsequent stroke that may occur with vasospasm in the setting of subarachnoid hemorrhage) within 5 days of the initial procedure
• M1382 – Patient encounter during the performance period with place of service code 11
• M1383 – Acute pvd
• M1384 – Patients who died during the performance period
• M1385 – Documentation of patient reasons for patients who were not seen for the second pam survey (e.g., less than four months between baseline pam assessment and follow-up
• M1386 – Patients with an excisional surgery for melanoma or melanoma in situ in the past 5 years with an initial ajcc staging of 0, i, or ii at the start of the performance period
• M1387 – Patients who died during the performance period
• M1390 – Patients who do not have a documented exam performed for recurrence of melanoma or no documentation within the performance period
• M1391 – All patients who were diagnosed with recurrent melanoma during the current performance period
• M1392 – Documentation of patient reasons for no examination, i.e., refusal of examination or lost to follow-up (documentation must include information that the clinician was unable to reach the patient by phone, mail or secure electronic mail - at least one method must be documented)
• M1393 – Patients who were not diagnosed with recurrent melanoma during the current performance period
• M1394 – Stages i-iii breast cancer
• M1395 – Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
• M1396 – Patients on a therapeutic clinical trial
• M1397 – Patients with recurrence/disease progression